Skip to main content
. 2018 Jun 29;9:2546. doi: 10.1038/s41467-018-04647-1

Table 1.

SL partners and corresponding drug combinations tested in patient-derived melanoma cell lines

graphic file with name 41467_2018_4647_Figa_HTML.gif

The table shows the top two predicted cSL interactions tested in melanoma, the corresponding drugs tested and the experiments’ outcome as evaluated by the combination index (CI) at 50% of cells are affected (CI < 0.7: strong synergism (blue), CI < 1: moderate synergism (green), and CI > 1: no synergism (white)).